Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 26,661 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Episodic Cluster Headache
Interventions: Civamide (Zucapsaicin), Sodium Chloride; Drug
Lead sponsor: Winston Laboratories; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 6
States / cities: San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more

Conditions: Bladder Perforation, Retropubic Midurethral Sling, Retropubic Hydrodissection
Interventions: retropubic hydrodissection; Procedure
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Congenital Ichthyosis
Interventions: PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%, Vehicle for PAT-001 0.2%; Drug
Lead sponsor: Patagonia Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: San Diego, California • New Haven, Connecticut • Chicago, Illinois + 2 more

Conditions: Liver Cancer
Interventions: nomogram-based selection for acute normovolemic hemodilution, standard selection for ANH based on a planned resection of 3 or more segments; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure
Interventions: Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 18
States / cities: Fountain Valley, California • Wilmington, Delaware • Fort Lauderdale, Florida + 15 more

Conditions: Rhinitis, Vasomotor
Interventions: GW685698X; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 38
States / cities: Beverly Hills, California • Huntington Beach, California • Mission Viejo, California + 34 more

Conditions: Hepatitis C, HIV Infections
Interventions: Double dose pegylated interferon with weight based Ribavirin, standard dose pegylated interferon alfa -2a and ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Overactive Bladder, Urinary Urgency, Urinary Incontinence, Urge Urinary Incontinence
Interventions: Patient-directed follow up; Behavioral
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: Ibrutinib, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 28
States / cities: Huntsville, Alabama • Avondale, Arizona • Daly City, California + 24 more

Conditions: Diabetes
Interventions: Community health worker education, Cell phone text messaging; Behavioral
Lead sponsor: Sinai Health System; Other
Eligibility: 18 Years to 64 Years
Enrollment: 272 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Dermatitis, Atopic
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 387 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 29
States / cities: Birmingham, Alabama • Encinitas, California • San Diego, California + 21 more

Conditions: Long COVID, Post-COVID Syndrome, Post COVID-19 Condition
Interventions: REGENECYTE, Placebo; Biological
Lead sponsor: StemCyte, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: Rheumatoid Arthritis
Interventions: GP2013, MabThera, Rituxan; Biological
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 16
States / cities: Los Angeles, California • Lexington, Kentucky • Cumberland, Maryland + 13 more

Conditions: Hyperkalemia, Chronic Kidney Disease, Kidney Dysfunction
Interventions: Zirconium silicate (ZS), Placebo; Drug
Lead sponsor: ZS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Tempe, Arizona • Costa Mesa, California • Edgewater, Florida + 6 more

Conditions: Labor Pain, Tocophobia
Interventions: Mind in Labor (MIL): Working with Pain in Childbirth, Treatment as usual (TAU); Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chronic Kidney Disease and Hypertension
Interventions: Baxdrostat/dapagliflozin, Placebo/dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 133
States / cities: Fairhope, Alabama • Sun City, Arizona • Tucson, Arizona + 117 more

Conditions: Non-small Cell Lung Cancer
Interventions: TH-302 combination with pemetrexed, Matched placebo in combination with pemetrexed; Drug
Lead sponsor: ImmunoGenesis; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 29
States / cities: Birmingham, Alabama • Chandler, Arizona • Encinitas, California + 25 more

Conditions: ALS - Amyotrophic Lateral Sclerosis
Interventions: powered neck exoskeleton; Device
Lead sponsor: University of Utah; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Pneumonia, Viral
Interventions: Reparixin, Placebo; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Greenwood, Indiana

Conditions: Non-Constipation Irritable Bowel Syndrome
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 88
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 83 more

Conditions: Healthy Volunteers
Interventions: CC-11050; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
Interventions: Extended release niacin, Placebo; Drug · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Infertility, Vitamin D Deficiency
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Chicago, Illinois

Conditions: Irritable Bowel Syndrome Characterized by Constipation
Interventions: Linaclotide, Placebo; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 79
States / cities: Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more

Search by objective public record fields.

Intranasal Civamide for Episodic Cluster Headache

Retropubic Hydrodissection and Trocar-induced Bladder Perforation During Retropubic Midurethral Slings

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

Controlled Trial Comparing Nomogram-based Versus Standard Allocation of Acute Normovolemic Hemodilution (ANH) During Hepatic Resection

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Study Of Adults And Adolescents With Vasomotor Rhinitis

Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients

Optimal Injection Interval for Intra-Detrusor Botulinum Toxin

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Controlling Hyperglycemia Among Minority Population

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia

Prenatal Education About Reducing Labor Stress (PEARLS)

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer

Evaluation of a Structurally Suitable Neck Exoskeleton in Patients With Amyotrophic Lateral Sclerosis

Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

Effect of Vitamin D Supplementation on In-vitro Fertilization (IVF) Outcomes

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)